Initial recruitment is on track for the Phase III pivotal study (TOZ-PD) of Biotie’s lead product candidate, tozadenant. Tozadenant offers a novel mechanism of action for the treatment of Parkinson’s disease (PD) patients experiencing motor fluctuations on levodopa. Top-line data from the double-blind portion of the trial are expected by end 2017. Meanwhile, two other products, SYN120 (Parkinson’s disease dementia, PDD) and BTT1023 (primary sclerosing cholangitis, PSC), are
20 Nov 2015
Pipeline progressing on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pipeline progressing on track
- Published:
20 Nov 2015 - Author:
- Pages:
Initial recruitment is on track for the Phase III pivotal study (TOZ-PD) of Biotie’s lead product candidate, tozadenant. Tozadenant offers a novel mechanism of action for the treatment of Parkinson’s disease (PD) patients experiencing motor fluctuations on levodopa. Top-line data from the double-blind portion of the trial are expected by end 2017. Meanwhile, two other products, SYN120 (Parkinson’s disease dementia, PDD) and BTT1023 (primary sclerosing cholangitis, PSC), are